Bone Biologics shareholders approve 30M share increase and 1-for-2.5 to 1-for-10 reverse split

Bone Biologics Corp

• Stockholders elected directors Stroever, Angle, Gagnon, and Meikle; all received >90% of votes cast (excluding broker non-votes).
• Approved plan amendment increasing authorized shares by 30M to 30,629,489 for equity awards.
• Authorized board to implement reverse stock split in range of 1-for-2.5 to 1-for-10 at its discretion.
• Ratified Weinberg & Company as auditor for FY2025; advisory say-on-pay passed with 63% support.